Processa Pharmaceuticals, Inc. Operating Lease Right-of-Use Assets
Processa Pharmaceuticals, Inc. (PCSA) had Operating Lease Right-of-Use Assets of $24.32 thousand as of 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-03-18
- 2025-06-30: Operating Lease, Right-of-Use Asset $24.32K.
- 2025-03-31: Operating Lease, Right-of-Use Asset $47.74K.
- 2024-12-31: Operating Lease, Right-of-Use Asset $70.68K.
- 2023-12-31: Operating Lease, Right-of-Use Asset $146.06K.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2025-06-30 | $24.32K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $47.74K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $70.68K 10-K · filed 2026-03-18 |
| 2023-12-31 | $146.06K 10-K · filed 2025-03-20 |
| 2023-09-30 | $167.03K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $187.60K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $207.79K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $227.59K 10-K · filed 2024-03-29 |
| 2022-09-30 | $246.98K 10-Q · filed 2022-11-08 |
| 2022-06-30 | $28.89K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $51.62K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $74.18K 10-K · filed 2023-03-30 |
| 2021-09-30 | $95.93K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $117.24K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $138.11K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $158.56K 10-K · filed 2022-03-30 |
| 2020-09-30 | $159.20K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $179.59K 10-Q · filed 2020-08-05 |
| 2020-03-31 | $199.53K 10-Q · filed 2020-05-15 |
| 2019-12-31 | $219.07K 10-K · filed 2021-03-25 |
| 2019-09-30 | $238.19K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $256.92K 10-Q · filed 2019-08-14 |
| 2019-03-31 | $275.25K 10-Q · filed 2019-05-14 |
| 2019-01-02 | $293.20K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |